Instructions for Femoston Mini (Estradiol, Dydrogesterone) 28 pills
English product name
Femoston Mini®
Release form
Coated tablets
Description Femoston Mini:
The tablets are covered with a yellow film sheath, round, double-convex, with the engraving "379" on one side;
view of tablets on a cross section: white and rough surface tablets
1 tab.
didrogesteron: 2.5 mg
Estradiol hemihydrate: 0.517 mg,
which corresponds to Estradiol content 0.5 mg
Auxiliary substances: lactose monohydrate - 117.4 mg, hypromellose (HPMC 2910) - 2.8 mg, corn starch - 14.7 mg, silicon dioxide colloidal - 1.4 mg, magnesium stearate - 0.7 mg.
Film sheath composition: YELLOW 1* film coating (macrogol 3350 - 20.2%, polyvinyl alcohol - 40%, talc - 14.8%, titanium dioxide (E171) - 20.55%, iron oxide yellow (E172) - 4.45%) - 4 mg.
ready-made film coating of identical composition, e.g. Opadry® II yellow 85F32331, may be used.
ATC Codes
G03FA14 Dydrogesterone and Estrogen
Clinical and pharmacological groups / Group affiliation
Antimenopausal drug
Active ingredient Femoston Mini
dydrogesteron
Estradiol
Pharmaco-therapeutic group
Antimenopausal agent combined (estrogen + gestagen)
Storage conditions
The drug should be stored out of the reach of children at a temperature not exceeding 25 ° C.
Shelf life
Shelf life - 4 years. Do not use after the expiration date.
Testimony Femoston Mini:
- hormone replacement therapy for estrogen-deficiency disorders in postmenopausal women (not earlier than twelve months after the last menstruation).
Method of use, course and dosage Femoston Mini:
The drug is taken inside, daily for 28 days, in continuous mode one tablet per day (preferably at the same time of day), regardless of the meal.
When switching from another continuous sequential or cyclic mode of taking the drug, you should finish the current cycle, and then go to the drug Femoston® mini.
Patients who do not receive DHT medication or who are transitioning from continuous use of DHT combination drugs can start taking Phemoston® mini any day.
If the patient has missed the next dose, the pill must be taken within 12 hours after the usual time of administration; Otherwise, you should not take the tablet, the next day you should take the tablet at normal time. Skipping taking the drug may increase the likelihood of a "breakthrough" uterine bleeding or smearing blood secretions.
To begin and continue treatment of GST-related estrogen deficiency disorders, the combination of didrogesteron and Estradiol should be administered at the lowest effective dose and for the shortest period of time (see Special Instructions). Continuous combination therapy can be started with Femoston® mini depending on the time after menopause and the severity of estrogen deficiency symptoms.
The use of the combined drug for ZGT Femoston® mini in women with natural menopause can begin no earlier than twelve months after the last menstruation. Women who have menopause as a result of surgery may start taking the drug immediately (as prescribed by a doctor if symptoms occur).
Indications for the use of Femoston® mini in children are absent.
Women over the age of 65 have no experience with the drug.
Estrogens can cause fluid retention in the body, so patients with kidney disorders should be monitored by a doctor.
Acute or chronic liver diseases currently or in anamnesis (prior to normalization of liver functional samples) are a contraindication to the use of the drug.
Use in renal dysfunction Dydrogesterone
With caution, the drug should be prescribed for renal failure.
Use in case of impaired liver function
Acute or chronic liver disease at present or in the anamnesis (before the normalization of liver function tests) is a contraindication to the use of the drug.
Terms of implementation
The drug is dispensed by prescription.
Use in elderly patients
There is no experience with the use of the drug in women over the age of 65 years.
Use in children Dydrogesterone
Indications for the use of the drug Femoston® mini in children are absent.
- Nosology Femoston Mini (ICD codes)
- N95.1
- Menopause and menopause in women
- N95.3
- Conditions associated with artificially induced menopause
pharmachologic effect:
Estradiol
Estradiol hemihydrate, which is part of the drug Femoston® mini, when dissolved, passes into 17-β-estradiol, identical to endogenous human Estradiol, which is the most active estrogen.
Estradiol replenishes the deficiency of estrogen in the body in postmenopausal women and reduces the severity of menopausal symptoms.
Didrogesterone
Dydrogesterone is a progestogen that is effective when taken orally and has activity similar to parenterally administered progesterone.
Because estrogens promote endometrial proliferation, hormone replacement therapy (HRT) with estrogen alone increases the risk of endometrial hyperplasia and cancer. The inclusion of dydrogesterone significantly reduces the increased risk of endometrial hyperplasia in women with a preserved uterus under the influence of estrogens.
